Incyte Corp (NASDAQ:INCY)
| 74.86 Delayed Data As of Jan 14 |  +1.23 / +1.67%Today’s Change | 61.91 Today|||52-Week Range 101.47 | +1.99% Year-to-Date |
Latest INCY News | Press Releases
| Dodge & Cox Global Stock Fund's 4th-Quarter Commentary Jan 17 / GuruFocus News - Paid Partner Content | AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis Jan 17 / Zacks.com - Paid Partner Content |
| Dodge & Cox Stock Fund's 4th-Quarter Commentary Jan 17 / GuruFocus News - Paid Partner Content | AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS Jan 10 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 73.65 |
| Today’s open | 73.48 |
| Day’s range | 72.83 - 74.94 |
| Volume | 1,580,839 |
| Average volume (3 months) | 2,079,671 |
| Market cap | $16.5B |
Data as of 4:00pm ET, 01/14/2022
Growth & Valuation
| Earnings growth (last year) | -165.21% |
| Earnings growth (this year) | +288.76% |
| Earnings growth (next 5 years) | +60.89% |
| Revenue growth (last year) | +23.53% |
| P/E ratio | 30.9 |
| Price/Sales | 7.11 |
| Price/Book | 6.29 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALNYAlnylam Pharmaceutic... | +0.50 | +0.34% |
| VTRSViatris Inc | +0.20 | +1.33% |
| CTLTCatalent Inc | -1.74 | -1.58% |
| HZNPHorizon Therapeutics... | +0.70 | +0.77% |
Data as of 4:00pm ET, 01/14/2022
Financials
| Next reporting date | February 17, 2022 |
| EPS forecast (this quarter) | $0.58 |
| Annual revenue (last year) | $2.7B |
| Annual profit (last year) | -$295.7M |
| Net profit margin | -11.09% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
